Clinical Trial Update: A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics [Phase 1]

View source ↗

Summary

A first-in-human, single-ascending-dose Phase 1 study of the biologic IBI3002 in healthy participants and mild-to-moderate asthmatics has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• IBI3002

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Healthy Participants, Asthma | Phase 1 | Status: COMPLETED